en

Taken Up Into Glory

We are to fulfill the mission God has called each of us to complete.




en

How to Live When You Learn You Aren’t a Super-Hero

In the midst of life’s woundability, what is your foundation?




en

[ASAP] MymA Bioactivated Thioalkylbenzoxazole Prodrug Family Active against <italic toggle="yes">Mycobacterium tuberculosis</italic>

Journal of Medicinal Chemistry
DOI: 10.1021/acs.jmedchem.0c00003




en

[ASAP] A Selective Modulator of Peroxisome Proliferator-Activated Receptor ? with an Unprecedented Binding Mode

Journal of Medicinal Chemistry
DOI: 10.1021/acs.jmedchem.9b01786




en

[ASAP] Imidazo[1,2-<italic toggle="yes">a</italic>]pyridine Derivatives as Aldehyde Dehydrogenase Inhibitors: Novel Chemotypes to Target Glioblastoma Stem Cells

Journal of Medicinal Chemistry
DOI: 10.1021/acs.jmedchem.9b01910




en

[ASAP] Synthesis and Structure–Activity Relationships of Arylsulfonamides as AIMP2-DX2 Inhibitors for the Development of a Novel Anticancer Therapy

Journal of Medicinal Chemistry
DOI: 10.1021/acs.jmedchem.9b01961




en

[ASAP] Pyridine-Embedded Phenothiazinium Dyes as Lysosome-Targeted Photosensitizers for Highly Efficient Photodynamic Antitumor Therapy

Journal of Medicinal Chemistry
DOI: 10.1021/acs.jmedchem.0c00280




en

[ASAP] Discovery of Orally Bioavailable Chromone Derivatives as Potent and Selective BRD4 Inhibitors: Scaffold Hopping, Optimization, and Pharmacological Evaluation

Journal of Medicinal Chemistry
DOI: 10.1021/acs.jmedchem.0c00035




en

[ASAP] Design and Synthesis of Bitopic 2-Phenylcyclopropylmethylamine (PCPMA) Derivatives as Selective Dopamine D3 Receptor Ligands

Journal of Medicinal Chemistry
DOI: 10.1021/acs.jmedchem.9b01835




en

[ASAP] Discovery and Development of S6821 and S7958 as Potent TAS2R8 Antagonists

Journal of Medicinal Chemistry
DOI: 10.1021/acs.jmedchem.0c00388




en

[ASAP] Discovery and Structure–Activity Relationship Study of (<italic toggle="yes">Z</italic>)-5-Methylenethiazolidin-4-one Derivatives as Potent and Selective Pan-phosphatidylinositol 5-Phosphate 4-Kinase Inhibitors

Journal of Medicinal Chemistry
DOI: 10.1021/acs.jmedchem.0c00227




en

[ASAP] Discovery of M-808 as a Highly Potent, Covalent, Small-Molecule Inhibitor of the Menin–MLL Interaction with Strong <italic toggle="yes">In Vivo</italic> Antitumor Activity

Journal of Medicinal Chemistry
DOI: 10.1021/acs.jmedchem.0c00547




en

[ASAP] Bioisosteric Discovery of NPA101.3, a Second-Generation RET/VEGFR2 Inhibitor Optimized for Single-Agent Polypharmacology

Journal of Medicinal Chemistry
DOI: 10.1021/acs.jmedchem.9b01336




en

[ASAP] Structure-Based Design of Highly Potent HIV-1 Protease Inhibitors Containing New Tricyclic Ring P2-Ligands: Design, Synthesis, Biological, and X-ray Structural Studies

Journal of Medicinal Chemistry
DOI: 10.1021/acs.jmedchem.0c00202




en

[ASAP] Design, Synthesis, and Mechanism Study of Benzenesulfonamide-Containing Phenylalanine Derivatives as Novel HIV-1 Capsid Inhibitors with Improved Antiviral Activities

Journal of Medicinal Chemistry
DOI: 10.1021/acs.jmedchem.0c00015




en

[ASAP] Design and Characterization of the First Selective and Potent Mechanism-Based Inhibitor of Cytochrome P450 4Z1

Journal of Medicinal Chemistry
DOI: 10.1021/acs.jmedchem.0c00101




en

[ASAP] Dual-Target Inhibitors Based on HDACs: Novel Antitumor Agents for Cancer Therapy

Journal of Medicinal Chemistry
DOI: 10.1021/acs.jmedchem.0c00491




en

[ASAP] Degradation versus Inhibition: Development of Proteolysis-Targeting Chimeras for Overcoming Statin-Induced Compensatory Upregulation of 3-Hydroxy-3-methylglutaryl Coenzyme A Reductase

Journal of Medicinal Chemistry
DOI: 10.1021/acs.jmedchem.0c00339




en

[ASAP] Targeting ALK2: An Open Science Approach to Developing Therapeutics for the Treatment of Diffuse Intrinsic Pontine Glioma

Journal of Medicinal Chemistry
DOI: 10.1021/acs.jmedchem.0c00395




en

[ASAP] p62/SQSTM1, a Central but Unexploited Target: Advances in Its Physiological/Pathogenic Functions and Small Molecular Modulators

Journal of Medicinal Chemistry
DOI: 10.1021/acs.jmedchem.9b02038




en

[ASAP] Discovery of Potent, Selective, and Orally Bioavailable Inhibitors of USP7 with In Vivo Antitumor Activity

Journal of Medicinal Chemistry
DOI: 10.1021/acs.jmedchem.0c00245




en

[ASAP] Optimization of Potent ATAD2 and CECR2 Bromodomain Inhibitors with an Atypical Binding Mode

Journal of Medicinal Chemistry
DOI: 10.1021/acs.jmedchem.0c00021




en

[ASAP] Design of Hydrazide-Bearing HDACIs Based on Panobinostat and Their p53 and FLT3-ITD Dependency in Antileukemia Activity

Journal of Medicinal Chemistry
DOI: 10.1021/acs.jmedchem.0c00442




en

[ASAP] Discovery of Potent Inhibitors against P-Glycoprotein-Mediated Multidrug Resistance Aided by Late-Stage Functionalization of a 2-(4-(Pyridin-2-yl)phenoxy)pyridine Analogue

Journal of Medicinal Chemistry
DOI: 10.1021/acs.jmedchem.0c00337




en

[ASAP] Discovery of <italic toggle="yes">N</italic>-Ethyl-4-[2-(4-fluoro-2,6-dimethyl-phenoxy)-5-(1-hydroxy-1-methyl-ethyl)phenyl]-6-methyl-7-oxo-1<italic toggle="yes">H</italic>-pyrrolo[2,3-<italic toggle=&q

Journal of Medicinal Chemistry
DOI: 10.1021/acs.jmedchem.0c00628




en

[ASAP] Discovery of a Silicon-Containing Pan-Genotype Hepatitis C Virus NS5A Inhibitor

Journal of Medicinal Chemistry
DOI: 10.1021/acs.jmedchem.0c00082




en

[ASAP] Ruthenium(II) Complex Containing a Redox-Active Semiquinonate Ligand as a Potential Chemotherapeutic Agent: From Synthesis to <italic toggle="yes">In Vivo</italic> Studies

Journal of Medicinal Chemistry
DOI: 10.1021/acs.jmedchem.0c00431




en

[ASAP] Drug Research Meets Network Science: Where Are We?

Journal of Medicinal Chemistry
DOI: 10.1021/acs.jmedchem.9b01989




en

[ASAP] Molecular Basis for Omapatrilat and Sampatrilat Binding to Neprilysin—Implications for Dual Inhibitor Design with Angiotensin-Converting Enzyme

Journal of Medicinal Chemistry
DOI: 10.1021/acs.jmedchem.0c00441




en

[ASAP] Discovery of Selective, Covalent FGFR4 Inhibitors with Antitumor Activity in Models of Hepatocellular Carcinoma

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.9b00601




en

[ASAP] Progress in the Field of Aldehyde Dehydrogenase Inhibitors: Novel Imidazo[1,2-<italic toggle="yes">a</italic>]pyridines against the 1A Family

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.9b00686




en

[ASAP] Inhibitors of Hypoxia-Inducible Factors as Treatment for Cancer

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00116




en

[ASAP] Therapeutic Potential of Targeted Nanoparticles and Perspective on Nanotherapies

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00075




en

[ASAP] Synthesis of Novel G Factor or Chloroquine-Artemisinin Hybrids and Conjugates with Potent Antiplasmodial Activity

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.9b00669




en

[ASAP] Novel HIV-1 Protease Inhibitors with Morpholine as the P2 Ligand to Enhance Activity against DRV-Resistant Variants

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00043




en

[ASAP] Design, Synthesis, and Pharmacological Evaluation of Second Generation EZH2 Inhibitors with Long Residence Time

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00045




en

[ASAP] Substituted Naphthalenediimide Compounds Bind Selectively to Two Human Quadruplex Structures with Parallel Topology

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00041




en

[ASAP] Escaping from Flatland: Substituted Bridged Pyrrolidine Fragments with Inherent Three-Dimensional Character

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00039




en

[ASAP] Characterization of an Alginate Encapsulated LS180 Spheroid Model for Anti-colorectal Cancer Compound Screening

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00076




en

[ASAP] Structure Optimization of Gatastatin for the Development of ?-Tubulin-Specific Inhibitor

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.9b00526




en

[ASAP] Rationally Designed Covalent BCL6 Inhibitor That Targets a Tyrosine Residue in the Homodimer Interface

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00111




en

[ASAP] Pharmacophore-Based Virtual Screening for Identification of Negative Modulators of GLI1 as Potential Anticancer Agents

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.9b00639




en

[ASAP] Exploring the Implication of DDX3X in DENV Infection: Discovery of the First-in-Class DDX3X Fluorescent Inhibitor

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.9b00681




en

[ASAP] Discovery of BMS-986251: A Clinically Viable, Potent, and Selective ROR?t Inverse Agonist

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00063




en

[ASAP] New Dual CK2/HDAC1 Inhibitors with Nanomolar Inhibitory Activity against Both Enzymes

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.9b00561




en

[ASAP] Novel Dithiolane-Based Ligands Combining Sigma and NMDA Receptor Interactions as Potential Neuroprotective Agents

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00129